SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?


To: Rick Strange who wrote (1116)8/6/1998 10:04:00 AM
From: Filbert  Read Replies (1) | Respond to of 1491
 
Does anyone know if Pharmos is planning to be the manufacturer of HU-211? Or are they going to have their eventual partner do the manufacturing?

Thanks,

Filbert



To: Rick Strange who wrote (1116)8/6/1998 1:45:00 PM
From: crysball  Read Replies (1) | Respond to of 1491
 
Q3-98 EUROPEAN LAUNCH OF LOTEMAX & ALREX

Ariella, could you clarify the UK and Netherlands launches you mentioned in post 1115. Does PARS/BOL have regulatory approvals yet, as I've not seen these approvals announced? Secondly, history says there is a lag between approval date and product launch (The FDA approved Lotemax/Alrex 3/15 but it was June before BOL could get product out the door and the salesforce trained) and to me launch means product rolled out into the hands (eyes) of consumers.

Also any thoughts on whether filling the distribution pipeline in Europe might help Q3 & beyond, as approvals in Europe are country by country.

Do you happen to know if PARS cold license a CIS (formerly Soviet Union) Pharmaceutical Mfg. for Alrex or Lotemax within the limits of the BOL license.......i.e. is the BOL license by continent or by country?

Your concise, information-packed reports are greatly appreciated by this reader.

Best Regards,
Neil




To: Rick Strange who wrote (1116)8/7/1998 8:14:00 PM
From: Gabe Fernandez  Read Replies (1) | Respond to of 1491
 
Ariella : A business partner for phase 3 is imperative the credibility of multiple university centers with busy neuro trauma ICU would be a bonanza for world opinion.